Agenus (NASDAQ:AGEN) Upgraded by HC Wainwright to Buy Rating

Agenus (NASDAQ:AGEN) was upgraded by investment analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $25.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 400.00% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Agenus from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. B. Riley reiterated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Finally, Robert W. Baird upped their price objective on shares of Agenus from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, May 13th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Agenus has a consensus rating of “Hold” and a consensus target price of $13.50.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $5.00 on Wednesday. The stock has a market capitalization of $137.09 million, a price-to-earnings ratio of -0.44 and a beta of 1.48. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The company has a 50 day moving average price of $2.73 and a 200 day moving average price of $2.90.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. On average, sell-side analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC acquired a new stake in Agenus in the 4th quarter worth $55,000. Deutsche Bank AG grew its position in Agenus by 538.4% in the 4th quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 51,566 shares during the last quarter. Bank of Montreal Can acquired a new stake in Agenus in the 4th quarter worth $69,000. Gilead Sciences Inc. acquired a new stake in Agenus in the 4th quarter worth $635,000. Finally, B. Riley Financial Inc. acquired a new stake in Agenus in the 4th quarter worth $2,074,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.